Last reviewed · How we verify
SITAXENTAN
Sitaxentan is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its unique mechanism of action. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | SITAXENTAN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- COMPERA / COMPERA-KIDS
- Sitaxsentan in Proteinuric Chronic Kidney Disease (PHASE2)
- Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects (PHASE2)
- A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure (PHASE2)
- Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery (PHASE2)
- Pharmacogenomics in Pulmonary Arterial Hypertension
- Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
- Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |